Effects of antiretrovirals on major adverse cardiovascular events in the REPRIEVE trial: a longitudinal cohort analysis
Carl J. Fichtenbaum(Cancer Research And Biostatistics), Markella V. Zanni(Harvard University), Heather J. Ribaudo(Cancer Research And Biostatistics), Sarah M Chu(Harvard University), Indira Brar(Henry Ford Hospital), Cristina Gómez‐Ayerbe(Instituto Ramón y Cajal de Investigación Sanitaria), Javier Valencia(Asociación Civil Impacta Salud y Educación), Pamela S. Douglas(Duke University), Michael T. Lu(Cancer Research And Biostatistics), Carlos Malvestutto(The Ohio State University Wexner Medical Center), Gerald S. Bloomfield, Marissa R Diggs(Harvard University), Judith S. Currier(University of California, Los Angeles), Kathleen V. Fitch(Harvard University), Sara McCallum(Cancer Research And Biostatistics), Judith A. Aberg(Icahn School of Medicine at Mount Sinai), José Valdez Madruga(Hospital Nacional Dos de Mayo), Emma Smith(Menzies School of Health Research), Maya Watanabe(Cancer Research And Biostatistics)
Cited by 7
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Outcomes of Anatomical versus Functional Testing for Coronary Artery Disease
|New England Journal of Medicine|2015|1.5k
Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2017|1.3k